Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75years of age
Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75years of age
复制标题
评估他汀类药物治疗缓解 75 岁以下人群脑小血管疾病进展的有效性
DOI：
10.1186/s12877-020-01682-w
复制
发表时间：
2020-08-17
期刊：
影响因子：
4.1
通讯作者：
Liu, Zhendong
中科院分区：
文献类型：
--
作者：
Guo, Yuqi;Li, Yunpeng;Liu, Zhendong
背景
多项指南已推荐他汀类药物作为心血管疾病的一级预防用药。然而，他汀类药物治疗对脑小血管病（CSVD）的益处，尤其是在年龄≥75岁的成年人中，尚未得到充分评估。
方法
我们分析了一项基于人群的前瞻性队列研究以及一项随机、双盲、安慰剂对照临床试验的数据，以确定他汀类药物治疗是否有助于减缓年龄≥75岁的成年人中CSVD的进展。在队列研究中，827名参与者被认为符合条件并纳入基线分析。随后，781名参与者被纳入随访分析。在临床试验中，227名参与者被认为符合条件并用于基线和随访分析。
结果
在队列研究的基线水平，他汀组的白质高信号（WMH）体积、WMH与颅内体积（ICV）之比、Fazekas量表评分≥2的患病率、腔隙、血管周围间隙扩大（EPVS）以及微出血均显著低于非他汀组（所有P
BackgroundStatins have been recommended by several guidelines as the primary prevention medication for cardiovascular diseases. However, the benefits of statin therapy for cerebral small vessel disease (CSVD), particularly in adults >= 75years of age, have not been fully evaluated.MethodsWe analyzed the data from a prospective population-based cohort study and a randomized, double-blind, placebo-controlled clinical trial to determine whether statin therapy might aid in slowing the progression of CSVD in adults >= 75years of age. For the cohort study, 827 participants were considered eligible and were included in the baseline analysis. Subsequently, 781 participants were included in follow-up analysis. For the clinical trial, 227 participants were considered eligible and were used in the baseline and follow-up analyses.ResultsThe white matter hyperintensities (WMH) volume, the WMH-to-intracranial volume (ICV) ratio, the prevalence of a Fazekas scale score >= 2, lacunes, enlarged perivascular spaces (EPVS), and microbleeds were significantly lower in the statin group than the non-statin group at baseline in the cohort study (all P